Friday, November 6, 2015

7:00-7:45 am  Breakfast and Registration

7:45-8:05 am  Welcome Remarks
Kidney Cancer Association
Carolyn Konosky, M.B.A. and Toni K. Choueiri M.D.

Epidemiology and Management of Localized RCC
Moderator: E. Jason Abel, M.D., FACS

8:05-8:15 am  Improving Healthcare Delivery in Kidney Cancer
Brian Lane, M.D., Ph.D.

8:15-8:25 am  Update on Molecular and Genetic Characterization of RCC
Ari Hakimi, M.D.

8:25-8:45 am  Debate: Renal Mass Biopsy Should be Used for Most SRM
PRO: Antonio Finelli, M.D., MSc, FRCSC
CON: Bradley C. Leibovich, M.D., FACS

8:45-8:55 am  Contemporary Management of AML
Stephen A. Boorjian, M.D.

8:55-9:15 am  Debate: Best Treatment for T1a RCC in Healthy 65 Year Old Patient
Surveillance-
Michael A.S. Jewett, M.D., FRCSC
Ablation/Partial-
R. Houston Thompson, M.D.

9:15-9:25 am  The Future Use of SBRT in RCC Treatment
Michael Bassetti, M.D.

9:25-9:40 am  Break

Locally-Advanced RCC
Moderator: R. Houston Thompson, M.D.

9:40-9:50 am  Novel Imaging Techniques in RCC
Michael Gorin, M.D.

9:50-10:10 am  Debate: Optimal Treatment for cT1b Renal Mass in Patient with Normal GFR
Partial Nephrectomy-
Vitaly Margulis, M.D.
Radical Nephrectomy-
Steven C. Campbell, M.D., Ph.D.

10:10-10:20 am  Minimally Invasive Node Dissection for Locally Advanced RCC
James A. Porter, Jr., M.D.

10:20-10:40 am  Debate: Does Ischemia Still Matter
YES: Karim Touijer, M.D.
NO: Dipen J. Parekh, M.D.

10:40-10:50 am  Improving Patient Selection for Surgery in RCC with Thrombus
E. Jason Abel, M.D., FACS

10:50-11:00 am  Management of Local Recurrence After Radical Nephrectomy
Sarah Psutka, M.D., M.Sc.

11:00 - 11:05 am  Novel 3d Volume Analysis Reveals Primary Tumor Diameter is a Poor Predictor of Tumor Volume; Does Tumor Burden Actually Predict Survival After Cytoreductive Nephrectomy?
Michael L. Blute, Jr., M.D.

11:05 - 11:10 am  Oncologic Surveillance Following Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach
Suzanne B. Stewart-Merrill, M.D.

11:10-11:30 am  Andrew C. Novick Lecture
Paul Russo, M.D., FACS

11:30-12:30 pm  Lunch and Poster Display

Variant Histology RCC and Inherited VHL Disease
Moderator: Nizar M. Tannir, M.D., FACP

12:30-12:40 pm  VHL Syndrome and Hemangio blastsoma Management
Eric Jonasch, M.D.

12:40-12:50 pm  Chromophobe RCC: TCGA and Other Updates
Payal Kapur, M.D.

12:50-1:05 pm  Papillary RCC: TCGA and Other Updates
Chad Creighton, Ph.D.

1:05-1:15 pm  Collecting Duct RCC
Gabriel Malouf, M.D., Ph.D.

1:15-1:25 pm  RCC with Sarcomatoid Dedifferentiation: New Insights
Jose A. Karam, M.D., FACS

1:25-1:40 pm  Clinical Trials in Non-Clear Cell RCC
Andrew Armstrong, M.D., ScM, FACP

1:40-1:45 pm  Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma
Moshe C. Ornstein, M.D., M.A.

1:45-2:05 pm  Break
Novel Immune Checkpoint Blockers
Moderators: Brian I. Rini, M.D.
Sabina Signoretti, M.D.

2:05-2:25 pm  The Biology of Checkpoint Inhibition
Gordon Freeman, Ph.D.

2:25-2:40 pm  Combination Immunotherapeutic Strategies in RCC: Preclinical Rationale
Charles G. Drake, M.D., Ph.D.

2:40-3:00 pm  Initial Therapy for mRCC: High-Dose IL-2 or a Checkpoint Inhibitor Trial?
Pro Immune Checkpoint Inhibitors: Hans Hammers, M.D.
Pro High-Dose IL-2: Neeraj Agarwal, M.D.

3:00-3:10 pm  The Really Important Questions: Current Immunotherapy Trials are Not Answering
David F. McDermott, M.D.

3:10-3:30 pm  Oncolytic Viruses
Daniel J. George, M.D.

3:30-3:45 pm  Management of Immune-Related Adverse Events
Michael A. Postow, M.D.

3:45 - 3:52 pm  Phase 1b Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naive Patients with Advanced Renal Cell Carcinoma
Toni K. Choueiri, M.D.

3:52 - 3:59 pm  Clinical, Pathologic and Genomic Profiles of Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma
Mark W. Ball, M.D.

3:59-4:15 pm  Break

Industry Science Experts (Non CME Session)
Moderator: Toni K. Choueiri, M.D.

4:15-4:30 pm  Optimization of Current Drugs in RCC and Upcoming Pipeline

4:30-4:45 pm  Inhibiting mTOR Complex: Biology and Targets

4:45-5:05 pm  The Next Generation of Immunotherapy Biomarkers

5:05-5:20 pm  Targeting HIF-2: Myth or Reality?

5:20 - 5:35 pm  Computational Tools for Network-Based Drug Discovery

5:35-5:45 pm  Audience Questions

5:45 pm  Adjourn

6:00-8:00 pm  Evening Reception at the hotel's Bay Front Terrace South
Special Seminar: KCA Role in Young Investigators’ Careers
Moderators: W. Kimryn Rathmell, M.D., Ph.D.
Carolyn Konosky, M.B.A
8:45-9:20 am KCA Role in Young Investigators’ Careers
Thai Ho, M.D., Ph.D.
Brian Lane, M.D., Ph.D.
Eliezer M. Van Allen, M.D.

9:20-9:50 am Eugene P. Schonfeld Lecture
Brian I. Rini, M.D.

9:50-10:20 am Break

RCC: Biology and Targets
Moderators: James Hsieh, M.D.
James Brugarolas, M.D., Ph.D.
10:20-10:35 am Applying Advanced Genomics to Therapy Selection
Sumanta Kumar Pal, M.D.
10:35-10:50 am Strategies to Circumvent Mechanisms of Resistance to VEGF TT
John M.L. Ebos, Ph.D.
10:50-11:05 am Epigenetics in RCC
Thai Ho, M.D., Ph.D.
11:05-11:20 am Patient Derived Xenograft Models and Potential Therapeutic Applications
Daniel Lindner, M.D., Ph.D.
11:20-11:35 am Genetically Engineered Mouse Models of RCC
William Y. Kim, M.D.
11:35-11:50 am Carbonic Anhydrase IX: Opportunities for Immune-Based Approaches
Wayne A. Marasco, M.D., Ph.D.
11:50-1:00 pm Lunch

Special Seminar: Statistical Considerations in RCC
Moderator: Walter M. Stadler, M.D., FACP
1:00-1:15 pm Biomarker-Based Studies
Meredith Regan, ScD
1:15-1:30 pm Considerations in Trials Design
Peter E. Thall, Ph.D.
1:30-2:30 pm Interactive Panel with Medical Oncologists and Surgeons (Case-Based)
Moderator: Christopher G. Wood, M.D., FACS
Panel: Elizabeth R. Plimack, M.D.,
Leonard J. Appleman, M.D.,
Viraj Master, M.D., Ph.D., FACS,
Brian Shuch, M.D.

2:30-3:00 pm Invited Abstracts
Moderators: Joshua M. Lang, M.D., M.S.
Jaime Cajigas, M.D.
2:30 - 2:37 pm Correlation of Tumor Programmed Death Ligand-1 (PD-L1) Expression and Response to Treatment with High-Dose Interleukin-2 (HD IL2) in Metastatic Clear Cell Renal Cell Carcinoma
David Gill, M.D.
2:37 - 2:44 pm Development of Novel Antibody-Free Method for Detecting Circulating Tumor Cell in Patients with Metastatic Renal Cell Carcinoma
Michael Gorin, M.D.
2:44 - 2:51 pm Molecular Predictors of Response and Survival Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Treated with Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGFTKIs)
Neeraj Agarwal, M.D.
2:51-3:00 pm Audience Questions

3:00-3:10 pm Honoring the Contributions of Dr. David A. Swanson, M.D. to the Kidney Cancer Association (Non CME)
Christopher G. Wood, M.D., FACS
3:10 pm Adjourn